Charles Schwab’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.4M | Buy |
3,219,656
+435,926
| +16% | +$1.66M | ﹤0.01% | 2027 |
|
|
2026
Q1 | $9.77M | Buy |
2,783,730
+30,387
| +1% | +$97.2K | ﹤0.01% | 2107 |
|
|
2025
Q4 | $7.52M | Buy |
2,753,343
+248,801
| +10% | +$576K | ﹤0.01% | 2264 |
|
|
2025
Q3 | $5.43M | Buy |
2,504,542
+588,056
| +31% | +$1.39M | ﹤0.01% | 2401 |
|
|
2025
Q2 | $3.3M | Buy |
1,916,486
+68,745
| +4% | +$171K | ﹤0.01% | 2502 |
|
|
2025
Q1 | $6.15M | Sell |
1,847,741
-141,599
| -7% | -$730K | ﹤0.01% | 2183 |
|
|
2024
Q4 | $14.7M | Buy |
1,989,340
+76,196
| +4% | +$706K | ﹤0.01% | 1845 |
|
|
2024
Q3 | $18M | Sell |
1,913,144
-71,801
| -4% | -$680K | ﹤0.01% | 1753 |
|
|
2024
Q2 | $15.9M | Buy |
1,984,945
+71,845
| +4% | +$770K | ﹤0.01% | 1803 |
|
|
2024
Q1 | $28.4M | Buy |
1,913,100
+166,077
| +10% | +$1.93M | 0.01% | 1403 |
|
|
2023
Q4 | $14.2M | Buy |
1,747,023
+54,490
| +3% | +$285K | ﹤0.01% | 1806 |
|
|
2023
Q3 | $7.7M | Buy |
1,692,533
+201,311
| +13% | +$1.31M | ﹤0.01% | 2054 |
|
|
2023
Q2 | $10.5M | Buy |
1,491,222
+435,370
| +41% | +$3.12M | ﹤0.01% | 1886 |
|
|
2023
Q1 | $6.45M | Buy |
1,055,852
+1,008
| +0.1% | +$6.96K | ﹤0.01% | 2087 |
|
|
2022
Q4 | $6.74M | Buy |
1,054,844
+27,384
| +3% | +$214K | ﹤0.01% | 2052 |
|
|
2022
Q3 | $9.84M | Buy |
1,027,460
+26,988
| +3% | +$311K | ﹤0.01% | 1841 |
|
|
2022
Q2 | $11M | Buy |
1,000,472
+292,976
| +41% | +$3.84M | ﹤0.01% | 1789 |
|
|
2022
Q1 | $11.8M | Buy |
707,496
+22,037
| +3% | +$341K | ﹤0.01% | 1861 |
|
|
2021
Q4 | $13.1M | Buy |
685,459
+19,563
| +3% | +$431K | ﹤0.01% | 1860 |
|
|
2021
Q3 | $16.4M | Sell |
665,896
-89,520
| -12% | -$2.11M | 0.01% | 1729 |
|
|
2021
Q2 | $19.7M | Buy |
755,416
+46,758
| +7% | +$1.22M | 0.01% | 1604 |
|
|
2021
Q1 | $22.4M | Buy |
708,658
+59,401
| +9% | +$2.46M | 0.01% | 1434 |
|
|
2020
Q4 | $30.1M | Buy |
649,257
+10,387
| +2% | +$412K | 0.01% | 1099 |
|
|
2020
Q3 | $21M | Buy |
638,870
+13,383
| +2% | +$410K | 0.01% | 1167 |
|
|
2020
Q2 | $17.2M | Sell |
625,487
-116,823
| -16% | -$3.84M | 0.01% | 1283 |
|
|
2020
Q1 | $22.2M | Buy |
742,310
+12,813
| +2% | +$340K | 0.01% | 943 |
|
|
2019
Q4 | $20.2M | Buy |
729,497
+28,564
| +4% | +$650K | 0.01% | 1206 |
|
|
2019
Q3 | $12.8M | Sell |
700,933
-1,321
| -0.2% | -$29.2K | 0.01% | 1444 |
|
|
2019
Q2 | $17.2M | Buy |
702,254
+34,480
| +5% | +$519K | 0.01% | 1241 |
|
|
2019
Q1 | $6.35M | Buy |
667,774
+29,194
| +5% | +$284K | ﹤0.01% | 1859 |
|
|
2018
Q4 | $5.65M | Buy |
638,580
+176,564
| +38% | +$1.7M | ﹤0.01% | 1842 |
|
|
2018
Q3 | $5.2M | Buy |
462,016
+55,324
| +14% | +$785K | ﹤0.01% | 2020 |
|
|
2018
Q2 | $5.21M | Buy |
406,692
+48,697
| +14% | +$712K | ﹤0.01% | 1979 |
|
|
2018
Q1 | $6.05M | Buy |
357,995
+55,820
| +18% | +$845K | ﹤0.01% | 1839 |
|
|
2017
Q4 | $2.42M | Buy |
302,175
+80,160
| +36% | +$644K | ﹤0.01% | 2244 |
|
|
2017
Q3 | $1.72M | Buy |
222,015
+12,883
| +6% | +$81.5K | ﹤0.01% | 2342 |
|
|
2017
Q2 | $1.54M | Buy |
209,132
+1,762
| +0.8% | +$11.2K | ﹤0.01% | 2315 |
|
|
2017
Q1 | $1.54M | Buy |
207,370
+11,220
| +6% | +$82.2K | ﹤0.01% | 2285 |
|
|
2016
Q4 | $1.36M | Buy |
196,150
+10,483
| +6% | +$72.1K | ﹤0.01% | 2326 |
|
|
2016
Q3 | $1.53M | Buy |
185,667
+26,290
| +16% | +$222K | ﹤0.01% | 2260 |
|
|
2016
Q2 | $1.29M | Buy |
159,377
+3,678
| +2% | +$23.1K | ﹤0.01% | 2258 |
|
|
2016
Q1 | $791K | Buy |
155,699
+4,001
| +3% | +$21.9K | ﹤0.01% | 2415 |
|
|
2015
Q4 | $1.17M | Buy |
151,698
+5,871
| +4% | +$40.7K | ﹤0.01% | 2320 |
|
|
2015
Q3 | $840K | Buy |
145,827
+9,363
| +7% | +$72.9K | ﹤0.01% | 2444 |
|
|
2015
Q2 | $1.25M | Buy |
+136,464
| New | +$1.52M | ﹤0.01% | 2317 |
|
Other funds holding IOVA
MFM
PAI
Charles Schwab's IOVA Position: Q2 2026 in Review
Charles Schwab increased its Iovance Biotherapeutics (IOVA) stake by 16% in Q2 2026, buying an estimated $1.66M and bringing the position to 3,219,656 shares worth $13.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2027.
Charles Schwab first reported a position in IOVA in Q2 2015 and has held it in 45 quarters since. The position peaked at $30.1M in Q4 2020. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.
- Charles Schwab held 3,219,656 shares of Iovance Biotherapeutics worth $13.4M as of Q2 2026.
- Charles Schwab bought 435,926 Iovance Biotherapeutics shares in Q2 2026, an estimated $1.66M.
- Iovance Biotherapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2027 holding.
- Charles Schwab first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 45 quarters since.
- Charles Schwab's Iovance Biotherapeutics position peaked at $30.1M in Q4 2020.
- 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.